US2023407341A1PendingUtilityA1

Using Truncated Guide RNAs (tru-gRNAs) to Increase Specificity for RNA-Guided Genome Editing

Assignee: MASSACHUSETTS GEN HOSPITALPriority: Mar 15, 2013Filed: Mar 6, 2023Published: Dec 21, 2023
Est. expiryMar 15, 2033(~6.6 yrs left)· nominal 20-yr term from priority
C12N 15/907C12N 9/22C12N 15/63C12Y 301/21004C12N 15/85C07K 14/005C07K 14/195C12N 9/0071C12N 9/1007C12N 9/16C12N 9/96C12N 15/01C12N 15/102C12N 15/1031C12N 15/11C07K 2319/00C07K 2319/01C12N 2710/00033C12N 2770/00033C12Y 114/11C12Y 201/01C12Y 301/00C12N 2800/80C12N 2310/20C07K 2319/80C12N 15/113C12N 9/10
87
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods for increasing specificity of RNA-guided genome editing, e.g., editing using CRISPR/Cas9 systems, using truncated guide RNAs (tru-gRNAs).

Claims

exact text as granted — not AI-modified
1 .- 28 . (canceled) 
     
     
         29 . A complex comprising:
 a  Streptococcus pyogenes  Cas9 protein; and   a  Streptococcus pyogenes  gRNA molecule that includes a complementarity region at the 5′ end of the gRNA consisting of 17-18 nucleotides that are complementary to 17-18 consecutive nucleotides of the complementary strand of a target sequence, wherein the target sequence is immediately 5′ of a protospacer adjacent motif,   wherein the gRNA is a single gRNA, and   wherein in the presence of an  S. pyogenes  Cas9 protein, the gRNA complementary region binds and directs the Cas9 protein to the target sequence.   
     
     
         30 . The complex of  claim 29 , wherein the Cas9 protein is a catalytically active nuclease. 
     
     
         31 . The complex of  claim 29 , wherein the Cas9 protein is a catalytically active nickase. 
     
     
         32 . The complex of  claim 29 , wherein the Cas9 protein is a catalytically inactive Cas9 protein. 
     
     
         33 . The complex of  claim 29 , wherein the complementarity region of the gRNA consists of 17 nucleotides. 
     
     
         34 . The complex of  claim 29 , wherein the complementarity region of the gRNA consists of 18 nucleotides. 
     
     
         35 . A DNA molecule encoding the complex of  claim 29 . 
     
     
         36 . A vector comprising the DNA molecule of  claim 35 . 
     
     
         37 . A host cell expressing the vector of  claim 36 . 
     
     
         38 . A complex comprising:
 a  Streptococcus pyogenes  Cas9 protein; and   a  Streptococcus pyogenes  gRNA molecule that includes a complementarity region at the end of the gRNA consisting of 17-18 nucleotides that are complementary to 17-18 consecutive nucleotides of the complementary strand of a target sequence, wherein the target sequence is immediately 5′ of a protospacer adjacent motif,   wherein the gRNA is a CRISPR RNA (crRNA), and   wherein in the presence of an  S. pyogenes  Cas9 protein, the gRNA complementary region binds and directs the Cas9 protein to the target sequence.   
     
     
         39 . A vector comprising a DNA molecule encoding:
 a  Streptococcus pyogenes  gRNA molecule that includes a complementarity region at the end of the gRNA consisting of 17-18 nucleotides that are complementary to 17-18 consecutive nucleotides of the complementary strand of a target sequence, wherein the target sequence is immediately 5′ of a protospacer adjacent motif,
 wherein the gRNA is a single gRNA or a CRISPR RNA (crRNA), and 
 wherein in the presence of an  S. pyogenes  Cas9 nuclease, the gRNA complementary region binds and directs the Cas9 nuclease to the target sequence; and 
 a promoter. 
   
     
     
         40 . The vector of  claim 39 , wherein the promoter is a constitutive promoter. 
     
     
         41 . The vector of  claim 39 , wherein the promoter is an inducible promoter. 
     
     
         42 . The vector of  claim 39 , wherein the promoter is a weak promoter. 
     
     
         43 . The vector of  claim 39 , wherein the expression vector is a bacterial expression vector. 
     
     
         44 . The vector of  claim 39 , wherein the expression vector is a eukaryotic expression vector. 
     
     
         45 . The vector of  claim 39 , wherein the promoter is an RNA Pol III promoter. 
     
     
         46 . The vector of  claim 39 , wherein the promoter is selected from an H1, U6, or 7SK promoter. 
     
     
         47 . The vector of  claim 39 , wherein the promoter is a T7 promoter. 
     
     
         48 . A host cell expressing the vector of  claim 47 .

Join the waitlist — get patent alerts

Track US2023407341A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.